Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1997; 78(01): 256-260DOI: 10.1055/s-0038-1657535 New recombinant products in the treatment of hemophilias Schattauer GmbH Stuttgart Second Generation, B-Domain Deleted Recombinant Factor VIII Erik Berntorp Department for Coagulation Disorders, University of Lund, University Hospital, Malmö, Sweden › Author Affiliations Recommend Article Abstract PDF Download Buy Article PDF (911 kb) References References 1 Gitschier J, Wood IW, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984; 312: 326-330 2 Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347 3 Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Opperman H, Keck R, Wood WI, Harkins RN, Tuddenham GD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-342 4 Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ. et al: Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1800-1805 5 Bray GL. Current status of clinical studies of recombinant factor VIII (Recombinate) in patients with hemophilia A. Transfus Med Rev 1992; 06: 252-255 6 Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993; 328: 453-459 7 Lusher JM. Considerations for current and future management of haemophilia and its complications. Haemophilia 1995; 01: 02-10 8 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G. the Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-2435 9 Ehrenforth S, Kreutz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Komhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598 10 Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 1993; 342: 462-464 11 Lusher JM. Recombinant clotting factor concentrates. In: Ballière's Clinical Haematology. Baillière Tindall, W.B. Saunders Company Ltd; London: 1996. 09. 291-303 12 Laurian Y, Dussaix E, Rothschild C, Mauser-Bunschoten EP, Gomperts ED, d'Oiron R, Tchernia G. Detection of human parvovirus B19 DNA by polymerase chain reaction in different factor VIII concentrates: Correlation with infectivity? XXII Int Congr Wld Fed Hemophilia, Dublin, 1996. Haemophilia 1996; 02 (Suppl 1) 97 (abstract) 13 Eis-Hübinger AM, Sasowski U, Brackmann HH, Kaiser R, Matz B, Schneweis KE. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products. Thromb Haemost 1996; 76: 1120 14 Arnold D. Virus safety considerations for recombinant factor VIII (rFVIII, Kogenate). Haemophilia 1995; 01 (Suppl 2) 22-23 15 Lind P, Larsson K, Spira J, Sydow-Backman M, Almstedt A, Gray E, Sandberg H. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur J Biochem 1995; 232: 19-27 16 Sandberg H, Brandt J, Ålin P, Strömberg S, Gray E, Bartfai J, Castro V. Glycosylation pattern of a B-domain-deleted recombinant factor VIII molecule (r-VIII SQ). XVth Cong Int Soc. Thromb Haemost; Jerusalem: 1995. (abstract) 17 Sandberg H, Bartfai J, Brandt J, Holmquist L, Kenne L, Lewin M, Lind P, Nilsson B, Sandberg M, Sebring S, Strömberg S, Alin P. Biochemical characteristics of a recombinant human factor VIII with a deleted B-domain. XXth Int Congr Wld Fed. Hemophilia; Athens: 1992. (abstract) 18 Berntorp E, Brackmann HH, Dechavanne M, Gazengel Cl, Johnsson H, Laurian Y, Tengborn L, Ståhl C, Holm R. Prophylactic treatment with a B-domain-deleted recombinant factor VIII (r-VIII SQ) in previously treated patients with severe haemophilia A. XVth Congr Int Soc. Thromb Haemost; Jerusalem: 1995. (abstract) 19 Oswaldsson U, Frank L, Sandberg H, Mikaelsson M. Comparison of factor VIII :C methods and reagents in the assay of factor VIII concentrates and post-injection patient plasma samples. XXI Int Congr Wld Fed. Hemophilia; Mexico City: 1994. (abstract) 20 Juhlin F, Moberg U, Oswaldsson U, Renlund S, Mikaelsson M. Stability and compatibility of reconstituted recombinant factor VIII SQ (r-VIII SQ) in a system for continuous infusion. XXII Int Congr Wld Fed. Haemophilia; Dublin: 1996 21 Smeds A-L, Ljungqvist Å, Ostlin A, Ljungquist C, Gaal A, Sandberg H, Rosenquist J, Mikaelsson M. The purification process for recombinant factor VIII SQ. XVth Congr Int Soc. Thromb Haemost; Jerusalem: 1995. (abstract) 22 Österberg T, Fatouros A. Development of a freeze-dried HSA-free formulation of a new recombinant factor VIII derivative, r-VIII SQ. XlVth Congr Int Soc. Thromb Haemost New York: 1993. (abstract) 23 Sandberg H, Lind P, Spira J. Characteristics of a new recombinant factor VIII derivative. XIIIth Congr Int Soc. Thromb Haemost; Amsterdam: 1991. (abstract) 24 Mikaelsson M, Eriksson B, Ljungqvist Å, Löfström A, Sandberg Wikén M, Österberg T. Preclinical characterization of recombinant factor VIII SQ. XXI Int Congr Wld Fed. Hemophilia; Mexico City: 1994. (abstract) 25 Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 1982; 60: 727-730 26 Morfini M, Lee M, Messori A. The design and analysis of halflife and recovery studies for factor VIII and IX. Thromb Haemost 1991; 66: 384-386 27 Berntorp E, Johnsson H, Tengborn L, Fijnvandraat K, Peters M, ten CateJW, Savidge G, Ståhl C, Holm R. Deletion of the B-domain in a recombinant factor VIII (r-VIII SQ) does not affect its main kinetic properties. Three pharmacokinetic studies in 36 patients with severe haemophilia A. XVth Congr Int Soc. Thromb Haemost; Jerusalem: 1995. (abstract) 28 Fijnvandraat K, Peters M, Ten CateKW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willeband factor antigen levels. Br J Haematol 1995; 91: 474-476 29 Nilsson IM, Berntorp E. Clinical efficacy of clotting factor concentrates: Survival, recovery and hemostatic capacity. In: Coagulation and Blood Transfusion. Smit SibingaT, Das PM, Mannucci PM. eds Kluwer Academic Publishers; 1991. pp 193-206 30 Tusell PuigbertJ, Spira J. One-year use of recombinant factor VIII SQ (r-VIII SQ, Pharmacia, Sweden) in patients with haemophilia A. XXII Ing Congr Wld Fed. Hemophilia; Dublin: 1996. Hemophilia 1996. 02. (suppl 01) 37 (abstract) 31 Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemopilia 1995; 1 (Suppl. 01) 08-13 32 Hay CRM, Spira J. Management of surgery in patients with haemophilia A using recombinant factor VIII (r-VIII SQ, Pharmacia, Sweden). XXII Int Congr Wld Fed. Haemophilia; Dublin: 1996. Haemophilia 1996. 02. (suppl 01) 53 (abstract) 33 Kreuz W, Spira J. Results from the first year of a recombinant factor VIII SQ (r-VIII SQ, Pharmacia, Sweden) study in previously untreated patients with haemophilia A. XXII Int Congr Wld Fed. Hemophilia; Dublin: 1996. Haemophilia 1996. 02. (suppl 01) 37 (abstract)
